CA2079585A1 - Ligand pour le produit du gene neu - Google Patents

Ligand pour le produit du gene neu

Info

Publication number
CA2079585A1
CA2079585A1 CA2079585A CA2079585A CA2079585A1 CA 2079585 A1 CA2079585 A1 CA 2079585A1 CA 2079585 A CA2079585 A CA 2079585A CA 2079585 A CA2079585 A CA 2079585A CA 2079585 A1 CA2079585 A1 CA 2079585A1
Authority
CA
Canada
Prior art keywords
pct
sec
activity
tyrosine kinase
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2079585A
Other languages
English (en)
Other versions
CA2079585C (fr
Inventor
Mark I. Greene
Kunio Dobashi
James G. Davis
Junji Hamuro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2079585A1 publication Critical patent/CA2079585A1/fr
Application granted granted Critical
Publication of CA2079585C publication Critical patent/CA2079585C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002079585A 1990-04-06 1991-04-04 Ligand pour le produit du gene neu Expired - Fee Related CA2079585C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50583790A 1990-04-06 1990-04-06
US505,837 1990-04-06

Publications (2)

Publication Number Publication Date
CA2079585A1 true CA2079585A1 (fr) 1991-10-07
CA2079585C CA2079585C (fr) 1997-01-07

Family

ID=24012070

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002079585A Expired - Fee Related CA2079585C (fr) 1990-04-06 1991-04-04 Ligand pour le produit du gene neu

Country Status (7)

Country Link
US (1) US5464751A (fr)
EP (1) EP0527802B1 (fr)
JP (1) JPH0776238B2 (fr)
AT (1) ATE153858T1 (fr)
CA (1) CA2079585C (fr)
DE (1) DE69126430T2 (fr)
WO (1) WO1991015230A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69229597T4 (de) * 1991-01-14 2000-08-17 Georgetown University Washingt Wachstumsfaktor-ligand, der an den erbb-2-rezeptor bindet und die zellulären reaktionen induziert
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7135456B1 (en) 1991-04-10 2006-11-14 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7115554B1 (en) 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7094749B1 (en) 1991-04-10 2006-08-22 Acorda Therapeutics, Inc. Glial mitogenic factors, their preparation and use
US7285531B1 (en) 1991-04-10 2007-10-23 Acorda Therapeutics, Inc. Method for prophylaxis or treatment of a nervous system, pathophysiological condition involving a glial growth factor sensitive cell by administration of a glial growth factor
US7319019B1 (en) 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5834229A (en) * 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US7037888B1 (en) 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
AU681095B2 (en) * 1992-09-29 1997-08-21 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
US5663144A (en) * 1995-05-03 1997-09-02 The Trustees Of The University Of Pennsylvania Compounds that bind to p185 and methods of using the same
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) * 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6541214B1 (en) * 1998-11-13 2003-04-01 Oregon Heath Science University N-terminally truncated HER-2/neu protein as a cancer prognostic indicator
US7396810B1 (en) * 2000-08-14 2008-07-08 Oregon Health Sciences University Compositions and methods for treating cancer by modulating HER-2 and EGF receptors
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
BR0012195A (pt) * 1999-06-25 2002-07-23 Genentech Inc Método para tratar câncer de próstata num ser humano, artigo de fabricação e uso de um anticorpo que liga erbb2
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US20040013667A1 (en) * 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US6627196B1 (en) 1999-08-27 2003-09-30 Genentech, Inc. Dosages for treatment with anti-ErbB2 antibodies
AU2001259271A1 (en) * 2000-04-28 2001-11-12 Millennium Pharmaceuticals, Inc. 14094, a novel human trypsin family member and uses thereof
KR101135233B1 (ko) * 2000-05-19 2012-04-12 제넨테크, 인크. ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
EP1384161A2 (fr) * 2000-09-07 2004-01-28 The Virtual Publishing Company Ltd Publication electronique et procedes et composants associes
JP2006516117A (ja) * 2002-11-21 2006-06-22 ジェネンテック・インコーポレーテッド 抗ＥｒｂＢ２抗体を用いた非悪性疾病または疾患の治療
CA2583230A1 (fr) * 2004-10-05 2006-04-20 Oregon Health And Science University Compositions et procedes de traitement de maladie

Also Published As

Publication number Publication date
DE69126430T2 (de) 1997-09-18
DE69126430D1 (de) 1997-07-10
US5464751A (en) 1995-11-07
CA2079585C (fr) 1997-01-07
JPH0776238B2 (ja) 1995-08-16
WO1991015230A1 (fr) 1991-10-17
EP0527802B1 (fr) 1997-06-04
ATE153858T1 (de) 1997-06-15
JPH06500072A (ja) 1994-01-06
EP0527802A1 (fr) 1993-02-24
EP0527802A4 (en) 1993-05-26

Similar Documents

Publication Publication Date Title
CA2079585A1 (fr) Ligand pour le produit du gene neu
ATE347585T1 (de) In-vitro wachstum von langerhans'schen inseln und ihre verwendungen
Haigler et al. Production and characterization of antibody blocking epidermal growth factor: receptor interactions
AU560340B2 (en) Rennin from recombinant dna
ES8700868A1 (es) Metodo de aislamiento de un fragmento de gen que codifica por lo menos una porcion de una proteina.
MY102472A (en) Preparation of funtional human urokinase proteins.
HUP9900899A2 (hu) Idegrendszeri eredetű magzati sejtvonalak felhasználása a transzplantációs terápiában
EP0216742A3 (fr) Facteurs de croissance
WO2000034474A3 (fr) Zvegf3 homologue du facteur de croissance
DK1032672T3 (da) DNA19355-polypeptid, en tumornekrosefaktor-homolog
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
DK1200561T3 (da) Rekombinant stabil celleklon, dens fremstilling og anvendelse
Salzman Animal Cell Cultures: Tissue culture is a powerful tool in the study of nutrition, physiology, virology, and genetics.
Lovell et al. Changes in the collagen of synovial membrane in rheumatoid arthritis and effect of D-penicillamine
DE69402313D1 (de) Expression von ntrki-abgeleiteten oncogenen in pciz pheochromocytomazellen und ihre verwendung im aufspüren von anti-tyrosinkinase-verbindungen
AU7508694A (en) Novel tyrosine kinase
Siraganian et al. Evidence that the “mouse mastocytoma” cell line (MCT-1) is of rat origin
MXPA01011158A (es) Factor de crecimiento homologo zvegf4.
ES8600518A1 (es) Metodo in vitro para detectar un estado maligno en un paciente humano.
ATE58397T1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
Stoscheck et al. Characteristics and uses of antibodies to the EGF-receptor kinase
EP0390327A3 (fr) Méthode pour la culture de cellules tissulaires
Sunshine et al. Is there a circulating human thymic factor that induces cyclic AMP synthesis?
EP0314496A3 (fr) Production d'hybridomes
Donnelly The mitogenic activities of bombesin GRP (18-27) and their analogues.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed